NASDAQ:XGN Exagen (XGN) Stock Price, News & Analysis $2.01 -0.02 (-0.99%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.00▼$2.0350-Day Range$1.74▼$2.1652-Week Range$1.30▼$2.95Volume11,501 shsAverage Volume38,572 shsMarket Capitalization$34.92 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Exagen alerts: Email Address Exagen MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside248.3% Upside$7.00 Price TargetShort InterestHealthy0.34% of Float Sold ShortDividend StrengthN/ASustainability-1.29Upright™ Environmental ScoreNews Sentiment0.96Based on 3 Articles This WeekInsider TradingAcquiring Shares$77,570 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.23) to ($1.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.88 out of 5 starsMedical Sector26th out of 936 stocksMedical Laboratories Industry1st out of 18 stocks 3.5 Analyst's Opinion Consensus RatingExagen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageExagen has only been the subject of 1 research reports in the past 90 days.Read more about Exagen's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.34% of the float of Exagen has been sold short.Short Interest Ratio / Days to CoverExagen has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exagen has recently decreased by 22.19%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldExagen does not currently pay a dividend.Dividend GrowthExagen does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExagen has received a 70.44% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Diagnostic test kits" and "Immunology laboratory services for research" products. See details.Environmental SustainabilityThe Environmental Impact score for Exagen is -1.29. Previous Next 3.3 News and Social Media Coverage News SentimentExagen has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Exagen this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Exagen to their MarketBeat watchlist in the last 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exagen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $77,570.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders26.10% of the stock of Exagen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.25% of the stock of Exagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exagen's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Exagen are expected to grow in the coming year, from ($1.23) to ($1.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exagen is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exagen is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExagen has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Exagen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Exagen Stock (NASDAQ:XGN)Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.Read More XGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XGN Stock News HeadlinesJuly 22, 2024 | globenewswire.comExagen to Announce Second Quarter 2024 Results on August 5, 2024May 19, 2024 | finance.yahoo.comExagen Inc. (XGN)July 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 15, 2024 | finance.yahoo.comExagen Inc (XGN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Margin ...May 15, 2024 | msn.comHealthcare Shares Soar Following Major Price Target IncreaseMay 14, 2024 | markets.businessinsider.comExagen’s Strong Q1 Earnings and Growth Potential Justify Buy RatingMay 14, 2024 | finance.yahoo.comExagen First Quarter 2024 Earnings: Beats ExpectationsMay 13, 2024 | msn.comExagen beats top-line and bottom-line estimates; raises FY24 outlookJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 13, 2024 | markets.businessinsider.comExagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full YearMay 13, 2024 | investorplace.comXGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q1 2024May 13, 2024 | globenewswire.comExagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full YearApril 30, 2024 | finance.yahoo.comExagen to Announce First Quarter 2024 Results on May 13, 2024April 26, 2024 | globenewswire.comExagen Inc. Announces Changes to the Board of DirectorsApril 16, 2024 | morningstar.comExagen Inc Ordinary SharesMarch 21, 2024 | finance.yahoo.comAnalyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Annual ReportMarch 20, 2024 | seekingalpha.comExagen Inc. (XGN) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Exagen on Strong Financials and Strategic Growth InitiativesSee More Headlines Receive XGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/27/2024Next Earnings (Confirmed)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:XGN CUSIPN/A CIK1274737 Webwww.exagen.com Phone760-560-1501FaxN/AEmployees174Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+248.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,690,000.00 Net Margins-34.74% Pretax Margin-34.68% Return on Equity-75.86% Return on Assets-33.26% Debt Debt-to-Equity Ratio0.96 Current Ratio4.83 Quick Ratio4.83 Sales & Book Value Annual Sales$55.73 million Price / Sales0.63 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book1.51Miscellaneous Outstanding Shares17,373,000Free Float12,839,000Market Cap$34.92 million OptionableOptionable Beta1.28 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Tina S. Nova Ph.D. (Age 70)Executive Chairman of the Board of Directors Comp: $65kMr. John Aballi (Age 39)CEO, President & Director Comp: $558.84kMr. Kamal Adawi M.S. (Age 45)MBA, CFO & Corporate Secretary Comp: $483.28kRyan DouglasInvestors Relations OfficerMr. John Wegener (Age 55)Senior Vice President of Sales and Marketing Dr. Andrew L. Concoff FACRM.D., Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory BoardDr. Michael I. Nerenberg M.D. (Age 69)Chief Medical Officer More ExecutivesKey CompetitorsBurning Rock BiotechNASDAQ:BNREnzo BiochemNYSE:ENZRenalytixNASDAQ:RNLXPsychemedicsNASDAQ:PMDBioNexus Gene LabNASDAQ:BGLCView All CompetitorsInsiders & InstitutionsPenbrook Management LLCSold 7,255 shares on 7/24/2024Ownership: 0.400%John AballiBought 40,401 shares on 5/16/2024Total: $77,569.92 ($1.92/share)Perkins Capital Management Inc.Sold 15,334 shares on 5/10/2024Ownership: 2.843%Kamal AdawiSold 12,784 sharesTotal: $24,417.44 ($1.91/share)John AballiSold 33,819 sharesTotal: $59,183.25 ($1.75/share)View All Insider TransactionsView All Institutional Transactions XGN Stock Analysis - Frequently Asked Questions How have XGN shares performed this year? Exagen's stock was trading at $1.99 at the start of the year. Since then, XGN stock has increased by 1.0% and is now trading at $2.01. View the best growth stocks for 2024 here. How were Exagen's earnings last quarter? Exagen Inc. (NASDAQ:XGN) posted its quarterly earnings data on Monday, May, 13th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.21. The firm had revenue of $14.42 million for the quarter, compared to analyst estimates of $13.20 million. Exagen had a negative trailing twelve-month return on equity of 75.86% and a negative net margin of 34.74%. What is Ron Rocca's approval rating as Exagen's CEO? 5 employees have rated Exagen Chief Executive Officer Ron Rocca on Glassdoor.com. Ron Rocca has an approval rating of 80% among the company's employees. When did Exagen IPO? Exagen (XGN) raised $50 million in an IPO on Thursday, September 19th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Cantor and William Blair acted as the underwriters for the IPO. Who are Exagen's major shareholders? Top institutional investors of Exagen include Penbrook Management LLC (0.40%). Insiders that own company stock include James L L Tullis, Kamal Adawi, Mark Hazeltine, John Aballi and Wendy S Johnson. View institutional ownership trends. How do I buy shares of Exagen? Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XGN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
